ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.
Coherus BioSciences Inc

Coherus BioSciences Inc (CHRS)

1.67
0.045
(2.77%)
Closed June 22 4:00PM
1.71
0.04
(2.40%)
After Hours: 7:46PM

Professional-Grade Tools, for Individual Investors.

Key stats and details

Current Price
1.71
Bid
1.67
Ask
1.72
Volume
1,301,809
1.62 Day's Range 1.72
1.4301 52 Week Range 5.465
Market Cap
Previous Close
1.625
Open
1.63
Last Trade Time
Financial Volume
$ 2,155,675
VWAP
1.6559
Average Volume (3m)
1,557,770
Shares Outstanding
114,725,740
Dividend Yield
-
PE Ratio
-0.80
Earnings Per Share (EPS)
-2.07
Revenue
257.24M
Net Profit
-237.89M

About Coherus BioSciences Inc

Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the... Coherus BioSciences Inc is a commercial-stage biopharmaceutical company building an innovative immuno-oncology franchise funded with cash generated by its diversified portfolio of FDA-approved therapeutics. Toripalimab is being evaluated in pivotal clinical trials for the treatment of cancers of the lung, breast, liver, skin, kidney, stomach, esophagus, and bladder. The company markets UDENYCA, a biosimilar of Neulasta in the United States, and expects to launch the FDA-approved Humira biosimilar YUSIMRY in the United States in 2023. The company is also developing CHS-305, a biosimilar of Avastin. The company generates revenue primarily from the United States. Show more

Sector
Biological Pds,ex Diagnstics
Industry
Biological Pds,ex Diagnstics
Website
Headquarters
Wilmington, Delaware, USA
Founded
1970
Coherus BioSciences Inc is listed in the Biological Pds,ex Diagnstics sector of the NASDAQ with ticker CHRS. The last closing price for Coherus BioSciences was $1.63. Over the last year, Coherus BioSciences shares have traded in a share price range of $ 1.4301 to $ 5.465.

Coherus BioSciences currently has 114,725,740 shares outstanding. The market capitalization of Coherus BioSciences is $190.44 million. Coherus BioSciences has a price to earnings ratio (PE ratio) of -0.80.

CHRS Latest News

PeriodChangeChange %OpenHighLowAvg. Daily VolVWAP
1-0.04-2.285714285711.751.751.5813177031.65262616CS
4-0.32-15.7635467982.032.031.5812432821.7681422CS
12-0.69-28.752.42.611.5815577702.06728156CS
26-0.32-15.7635467982.033.71.5837577492.51256883CS
52-2.13-55.468753.845.4651.430137277362.97047132CS
156-12.53-87.991573033714.2419.321.430120013395.33628592CS
260-20.02-92.130694891921.7323.911.430116489618.79296409CS

Market Movers

View all
  • Most Active
  • % Gainers
  • % Losers
SymbolPriceVol.
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SHCRSharecare Inc
$ 1.365
(76.27%)
56.33M
NXLNexalin Technologies Inc
$ 1.7499
(59.08%)
57.58M
FUFUBitFuFu Inc
$ 6.1209
(56.95%)
2.5M
SPECSpectaire Holdings Inc
$ 0.50
(47.06%)
65.27M
FLFVFeutune Light Acquisition Corporation
$ 2.5502
(-69.75%)
862.38k
FLFVUFeutune Light Acquisition Corporation
$ 2.75
(-66.83%)
16.5k
RWODRedwoods Acquisition Corporation
$ 2.34
(-60.34%)
155.96k
KAVLKaival Brands Innovations Group Inc
$ 1.23
(-57.14%)
4.92M
RWODURedwoods Acquisition Corporation
$ 3.24
(-56.28%)
1.47k
NVDANVIDIA Corporation
$ 126.57
(-3.22%)
658.13M
AREBAmerican Rebel Holdings Inc
$ 0.76
(152.49%)
371.46M
SIRISirius XM Holdings Inc
$ 2.94
(1.38%)
330.66M
AAPLApple Inc
$ 207.49
(-1.04%)
246.38M
NKLANikola Corporation
$ 0.3466
(5.16%)
193.36M

CHRS Discussion

View Posts
Monksdream Monksdream 2 months ago
CHRS under $3
👍️0
frans frans 4 months ago
short interest about 28.000.000 milj.up 7% today
👍️0
Mile High Marauder Mile High Marauder 4 months ago
Here is short interest link

https://www.nasdaq.com/market-activity/stocks/chrs/short-interest
👍️0
frans frans 4 months ago
you know how many shorts we have here to cover ????
my last buy was 2.08
👍️0
Mile High Marauder Mile High Marauder 4 months ago
I think selling these non core assets, with the probability of selling more has greatly diminished the need to raise money and has put some pressure on the shorts to cover some of this massive short. IMO
👍️ 1
frans frans 4 months ago
Coherus’ oncology assets include the UDENYCA® (pegfilgrastim-cbqv) franchise, with three FDA-approved presentations; LOQTORZI™ (toripalimab-tpzi), an FDA-approved, next-generation PD-1 inhibitor; and an immuno-oncology pipeline of next-generation tumor microenvironment oncology drug candidates.

Closing is anticipated in from jan 22
👍️0
Mile High Marauder Mile High Marauder 4 months ago
What fda news are u looking for?
👍️0
frans frans 4 months ago
up 14 % FDA news is coming
👍️0
frans frans 5 months ago
MM's we see an small cover now ? or company sell more ??,
👍️0
Mile High Marauder Mile High Marauder 5 months ago
27million share short. I wonder what the true valuation of the company is? I sure hope the shorts have to cover some day. I can’t say I’ve Seen a short this large on a listed stock. Implosion or explosion ,I guess only time will tell.
👍️0
moonurneighbor moonurneighbor 5 months ago
I think they are preparing for a sale
👍️0
Awl416 Awl416 5 months ago
Coherus Presents Positive Phase 2 Clinical Data on Casdozokitug, a First-in-Class IL-27-Targeted Antibody, at the 2024 ASCO GI Cancers Symposium
👍️0
frans frans 5 months ago
up from here now for the 1e FDA news
👍️0
frans frans 5 months ago
company dump big big here
👍️0
frans frans 5 months ago
have we an new company dump now ???????
👍️0
frans frans 5 months ago
now up from here and wait on FDA news (should be good)
👍️0
glenn1919 glenn1919 6 months ago
CHRS...........................https://stockcharts.com/h-sc/ui?s=CHRS&p=W&b=5&g=0&id=p86431144783
👍️0
tbonaces80 tbonaces80 6 months ago
Cup and handle formed
👍️0
tbonaces80 tbonaces80 6 months ago
We will test HOD. HH and HL’s
👍️0
Mile High Marauder Mile High Marauder 6 months ago
I find it hard to believe they’re going to dilute this company by 40% at this point Or at this price but you never know.
👍️0
Sierra20 Sierra20 6 months ago
Offering?
👍️0
eneels01 eneels01 6 months ago
Company needs to issue 40M shares at $2/sh. This would raise $80M, which would be enough to get through mid 2025…
👍️0
Mile High Marauder Mile High Marauder 7 months ago
21 million share short!! What is going on!
👍️0
Monksdream Monksdream 7 months ago
CHRS new 52 week low
👍️0
frans frans 7 months ago
about end dec.23 finish tests 400 peoples - FDA commercialization about june 24 if no problems
👍️0
eneels01 eneels01 7 months ago
Wow, instead of having a chance to go to $9, this stock has more of a chance to hit $1 by 2024. Oh well, I will just keep averaging down and sell when it eventually hits $5 again. Unfortunately that might not take place until 2025 or even 2026…
👍️0
frans frans 7 months ago
I selled and come back begin jan 24 after finish test 400 peoples about end dec. 23
👍️0
Mile High Marauder Mile High Marauder 7 months ago
Any idea who has this much stock to sell? I don’t see very many 5% holders.
👍️0
frans frans 8 months ago
what is going on here ??
👍️0
TimeFades TimeFades 8 months ago
Yup
👍️0
Monksdream Monksdream 8 months ago
For now
👍️0
TimeFades TimeFades 8 months ago
Looking strong
👍️0
Monksdream Monksdream 8 months ago
Few and far between in the biomed sector this year
👍️0
frans frans 8 months ago
slowly up from here
👍️0
Monksdream Monksdream 8 months ago
CHRS morning rally
👍️0
TimeFades TimeFades 8 months ago
Back in
👍️0
TimeFades TimeFades 8 months ago
Sold out first thing at 4 watching
👍️0
TheFinalCD TheFinalCD 8 months ago
WATCH 2:22
👍️0
Mile High Marauder Mile High Marauder 8 months ago
Didn’t mean dog
👍️0
Mile High Marauder Mile High Marauder 8 months ago
This dog has an 18 million shares short in it, somebody’s been betting big against it or think they know something we don’t
👍️0
TIMGZ TIMGZ 8 months ago
INSTITUTIONS ARE BUYING UP ALL AND EVERY POTENTIALS******STILL, IT WILL EVENTUALLY DRIZZLE DOWN
👍️0
TheFinalCD TheFinalCD 8 months ago
I bought the dip, but the float is practically owned by Institutions

thats the problem I see here

80% https://finviz.com/quote.ashx?t=CHRS&p=d
👍️0
TIMGZ TIMGZ 8 months ago
CHRS****OPPORTUNITY TO BUY MORE OR STILL WAIT FOR DIRECTION??????????
👍️0
TheFinalCD TheFinalCD 8 months ago
3.10 GOING WRONG WAY

MAYBE THE NEWS ISNT AS BIG AS HOPED??
👍️0
TheFinalCD TheFinalCD 8 months ago
LOQTORZI $CHRS

What is nasopharyngeal carcinoma? Nasopharyngeal carcinoma (also known as NPC) is a rare tumor of the head and neck which originates in the nasopharynx. The nasopharynx is located at the very back of the nose near the Eustachian tubes (Figure).

good part is

LOQTORZI is the first and only FDA-approved treatment for NPC
👍️0
TimeFades TimeFades 8 months ago
Moon?
👍️0
Runners123 Runners123 8 months ago
Coherus BioSciences, Inc. (“Coherus”, NASDAQ: CHRS), and Shanghai Junshi Biosciences Co., Ltd. (Junshi Biosciences, HKEX: 1877; SSE: 688180) today announced that the U.S. Food and Drug Administration (FDA) approved LOQTORZI™ (toripalimab-tpzi) in combination with cisplatin and gemcitabine for the first-line treatment of adults with metastatic or recurrent locally advanced NPC, and as monotherapy for the treatment of adults with recurrent, unresectable, or metastatic NPC with disease progression on or after platinum-containing chemotherapy. The approval was based on results of the JUPITER-02 Phase 3 study and the POLARIS-02 Phase 2 study and is irrespective of a patient’s PD-L1 status. LOQTORZI is a next-generation, programmed death receptor-1 (PD-1) monoclonal antibody that blocks PD-1 ligands PD-L1 and PD-L2 with high potency at a unique site on the PD-1 receptor, enabling the immune system to activate and kill the tumor.
In the JUPITER-02 Phase 3 study, LOQTORZI combined with chemotherapy significantly improved progression-free survival (PFS), reducing the risk of disease progression or death by 48% compared to chemotherapy alone. LOQTORZI also demonstrated a statistically significant and clinically meaningful improvement in overall survival (OS), with treatment resulting in a 37% reduction in the risk of death versus chemotherapy alone.

The safety profile of LOQTORZI was consistent with the PD-1 inhibitor class. The incidence of Grade ≥3 adverse events (AEs) (89.7% vs 90.2%) and fatal AEs (3.4% vs 2.8%) was similar between the two arms. AEs leading to discontinuation of LOQTORZI versus placebo (11.6% vs 4.9%), immune-related adverse events (irAEs) (54.1% vs. 21.7%), and Grade ≥3 irAEs (9.6% vs. 1.4%) were more frequent in the LOQTORZI arm.

In the POLARIS-02 clinical study LOQTORZI demonstrated durable antitumor activity in patients with recurrent or metastatic NPC who failed previous chemotherapy, with an objective response rate (ORR) of 20.5%, a disease control rate (DCR) of 40.0%, and a median OS of 17.4 months with an acceptable safety profile.

NPC is an aggressive cancer that starts in the nasopharynx, the upper part of the throat behind the nose and near the base of skull. Due to the location of the primary tumor, surgery is rarely an option, and patients with localized disease are treated primarily with radiation and chemotherapy. LOQTORZI is the first FDA-approved agent for NPC patients.

“LOQTORZI’s first approval is a pivotal event for Coherus as an innovative oncology company. As a next generation PD-1 inhibitor it is the keystone of our I-O strategy to extend cancer patient survival as shown with the impressive results in NPC,” said Denny Lanfear, Chairman and Chief Executive Officer of Coherus. “We are particularly excited to now turn our attention to developing LOQTORZI across multiple tumor types in combination with I-O agents that target the tumor microenvironment, such as our IL27-targeted antibody, casdozokitug, and our CCR8 inhibitor CHS-114, potentially greatly expanding the number of cancer patients achieving improved survival benefit.”

“Today’s FDA approval of LOQTORZI is very encouraging for those living with NPC who currently have very limited treatment options and are in need of new therapies to treat this aggressive and life-threatening form of cancer,” said Jong Chul Park, M.D., Assistant Professor, Harvard Medical School and attending physician at the Center for Head and Neck Cancers at Massachusetts General Hospital Cancer Center. “LOQTORZI is a new treatment option that has demonstrated the ability to significantly improve PFS and OS and should quickly emerge as the new standard of care when used in combination with chemotherapy.”

The recommended LOQTORZI dose with cisplatin and gemcitabine is 240 mg every three weeks until disease progression, unacceptable toxicity, or up to 24 months. The recommended LOQTORZI dose as a single agent for previously treated NPC is 3 mg/kg every two weeks until disease progression or unacceptable toxicity.

LOQTORZI is expected to be available in the United States in Q1 2024.

“The impressive results from JUPITER-02 and POLARIS-02 have provided conclusive evidence that establishes toripalimab, in combination with chemotherapy or as monotherapy, as the standard therapy for advanced NPC,” said Professor Ruihua Xu of Sun Yat-sen University Cancer Center, the principal investigator of JUPITER-02 and POLARIS-02. “This great achievement was only made possible through the solid foundation laid by countless oncology experts over decades of in-depth research, as well as the selfless dedication of the patients and research teams involved in our toripalimab studies. We hope that this promising therapy will close the treatment gap for international NPC patients struggling to find effective therapies, bringing them renewed hope for better survival.”

“We’re excited to reach another significant company milestone of ‘going overseas’,” said Dr. Ning LI, Chief Executive Officer of Junshi Biosciences. “Following etesevimab, toripalimab has become Junshi Biosciences’ second product to receive FDA approval for commercialization—an achievement that will further enhance the company’s international presence. Currently, the establishment of toripalimab’s global commercialization network is in progress, and the network aims to span over 50 countries. In accordance with the company’s ‘In China, For Global’ strategy, we will continue working with our collaborators to promote the commercialization of toripalimab in other regions, in order to provide innovative and high-quality drugs from China to more patients overseas.”
👍️0
TheFinalCD TheFinalCD 8 months ago
3.54
👍️0
TheFinalCD TheFinalCD 8 months ago
$CHRS 3.44 NHOD
👍️0
TheFinalCD TheFinalCD 8 months ago
https://investorshub.advfn.com/boards/msgsearchbyboard.aspx?boardid=12753&searchstr=CHRS&srchyr=2023
👍️0

Your Recent History

Delayed Upgrade Clock